Detail akcie Embecta Rg-WI online

Business Summary: Embecta Corp. is a global diabetes care company. It is focused on providing solutions to people living with diabetes. It has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It has clearance from the FDA for its proprietary disposable insulin delivery system, which is indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D).
Financial Summary: BRIEF: For the three months ended 31 December 2025, Embecta Corp revenues decreased less than 1% to $261.2M. Net income increased from $0K to $44.1M. Revenues reflect Safety segment increase of 9% to $37.3M, Syringes segment increase of 8% to $30.7M, International segment increase of 8% to $130.3M, also reflect Pen Needles segment decrease of 3% to $185.5M, Manufacturing Facility segment decrease of 15% to $4.1M, United States segment decrease of 8% to $130.9M.